Current stage-specific chemotherapeutic options in colon cancer

Expert Review of Anticancer Therapy

Volumn 5, Issue 4, 2005, Pages 695-704

  Martin, Michael J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chemotherapy; Colon cancer; Treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; UFT;

ADVANCED CANCER; ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; REVIEW; RISK BENEFIT ANALYSIS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; HUMANS; NEOPLASM STAGING; PATIENT CARE PLANNING;

EID: 24044505985     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.4.695     Document Type: Review

References (46)

1. Campo J, Comber H, Gavin AT. All-Ireland cancer statistics 1998-2000. Northern Ireland Cancer Registry/National Cancer Registry (2004).
2. Mulcahy MF, Benson AB. Recent and ongoing clinical trials for treating colorectal. cancer. Expert Opin. Investig. Drugs 11(6), 871-880 (2002).
3. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 96(19), 1420-1425 (2004).
4. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual, Sixth Edition. Springer-Verlag, NY, USA (2002).
5. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin. Oncol. 28(1 Suppl. 1), 20-24 (2001).
6. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for medicare beneficiaries with Stage II colon cancer. J. Clin. Oncol. 20(19), 3999-4005(2002).
7. The International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J. Clin. Oncol. 17(5), 1356-1363 (1999).
8. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four national surgical adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol. 17(5), 1349-1355 (1999).
9. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for Stage II and Stage III colon cancer: who benefits and by how much? J. Clin. Oncol 22(10), 1797-1806 (2004).
10. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004).
11. Gray RG, Barnwell J, Hills R, McConkey C, Williams N, Kerr D. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients. J. Clin. Oncol. 22(Suppl. 14S), 3501 (2004).
12. Benson AB, Schrag D, Somerfleld MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for Stage II colon cancer. J. Clin. Oncol. 22(16), 3408-3419 (2004).
13. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264(11), 1444-1450 (1990).
14. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc. Am. Soc. Clin. Oncol. 17, 982 (1998).
15. André T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in Stage II and III colon cancer: results of a randomized trial. J. Clin. Oncol. 21(15), 2896-2903 (2003).
16. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in Stage III colon cancer (intergroup trial CALGB C89803). J. Clin. Oncol. 22(14S), 3500 (2004).
17. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as fisrt-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355(9209), 1041-1047 (2000).
18. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343(13), 905-914 (2000).
19. Kohne C, Van Cutsem E, Wils J et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI group study 40986. Proc. Am. Soc. Clin. Oncol. 23, 217 (2004).
20. Cassidy J, Twelves C, Nowacki MP et al. Improved safety of capecitabine versus bolus 5-fluorouracil/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT Phase III study). Proc. Am. Soc. Clin. Oncol. 23, 219 (2004).
21. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to iv. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized Phase III trial. Ann. Oncol. 14(12), 1735-1743 (2003).
22. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R. A Phase III trial comparing oral UFT to FULV in Stage II and III carcinoma of the colon: results of NSABP Protocol C-06. J. Clin. Oncol. 22(14S), 3508 (2004).
23. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138), 1413-1418 (1998).
24. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000).
25. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22(1), 23-30 (2004).
26. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004).
27. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs. intravenous 5-fluofouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase III trials. Br. J. Cancer 90(6), 1190-1197 (2004).
28. Douillard JY, Hoff PM, Skillings JR et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20(17), 3605-3615 (2002).
29. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20(17), 3617-3627 (2002).
30. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004).
31. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
32. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21(1), 60-65 (2003).
33. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
34. de Gramont A, Cervantes A, Andre T et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. J. Clin. Oncol. 22(14S), 3525 (2004).
35. Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J. Clin. Oncol. 21(14), 2703-2707 (2003).
36. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22(7), 1209-1214 (2004).
37. Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup trial INT-0089. J. Clin. Oncol. 21(15), 2912-2919 (2003).
38. Goldstein NS. Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years. Recommendations for a minimum of recovered lymph nodes based on predictive probabilities. Am. J. Surg. Pathol. 26(2), 179-189 (2002).
39. Watanabe T, Wu T-T, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344(16), 1196-1206 (2001).
40. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247-257 (2003).
41. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23(3), 609-618 (2005).
42. Wang Y, Jatkoe T, Zhang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22(9), 1564-1571 (2004).
43. Rosenberg AH, Loehrer PJ, Needle MN et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 21, 536 (2002).
44. Lutz MP, Schöffski P, Folprecht G et al. A Phase I/II study of cetuximab (C225) plus irinotecan (CPT-11) and 24h infusional 5FU/folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR). Ann. Oncol. 13(5S), 73 (2002).
45. Van Laethem J-L, Raoul J-L, Mitry E et al. Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc. Am. Soc. Clin. Oncol. 22, 1058 (2003).
46. Sargent DJ, Wieand S, Benedetti J et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary end point for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. J. Clin. Oncol. 22(14S), 3502 (2004).